Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Total Non-Current Liabilities (2016 - 2025)

Guided Therapeutics' Total Non-Current Liabilities history spans 13 years, with the latest figure at $79000.0 for Q3 2025.

  • For Q3 2025, Total Non-Current Liabilities fell 44.37% year-over-year to $79000.0; the TTM value through Sep 2025 reached $79000.0, down 44.37%, while the annual FY2024 figure was $112000.0, 83.18% down from the prior year.
  • Total Non-Current Liabilities for Q3 2025 was $79000.0 at Guided Therapeutics, up from $35000.0 in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $1.8 million in Q4 2021 and bottomed at $35000.0 in Q2 2025.
  • The 5-year median for Total Non-Current Liabilities is $727000.0 (2023), against an average of $880263.2.
  • The largest annual shift saw Total Non-Current Liabilities soared 61.7% in 2022 before it plummeted 90.6% in 2024.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $1.8 million in 2021, then decreased by 22.95% to $1.4 million in 2022, then crashed by 51.74% to $666000.0 in 2023, then tumbled by 83.18% to $112000.0 in 2024, then fell by 29.46% to $79000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Total Non-Current Liabilities are $79000.0 (Q3 2025), $35000.0 (Q2 2025), and $96000.0 (Q1 2025).